Antiangiogenic therapy in diabetic nephropathy: A double‑edged sword (Review)

Tao, Qian-Ru; Chu, Yan; Wei, Lan; Tu, Chao; Han, Yuanyuan

doi:10.3892/mmr.2021.11899

Cited by 12 publications

(9 citation statements)

References 152 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These vectors have also helped preserve renal microvascular morphology and suppress the progression of AKI via the upregulation of vascular endothelial growth factor (VEGF) and angiopoietin [41]. Interestingly, the inhibition of VEGF also promoted structural and functional improvements in diabetes-induced chronic kidney disease [42,43]. These findings support the long-derived notion that repairing ischemic and toxic renal injuries depended critically on regulating a redundant, interactive network of cytokines and growth factors [44].…”

Section: Of 22mentioning

confidence: 80%

Still Finding Ways to Augment the Existing Management of Acute and Chronic Kidney Diseases with Targeted Gene and Cell Therapies: Opportunities and Hurdles

Corridon¹

2023

Preprint

View full text Add to dashboard Cite

The rising global incidence of acute and chronic kidney diseases has increased the demand for renal replacement therapy. This issue, compounded with the limited availability of viable kidneys for transplantation, has propelled the search for alternative strategies to address the growing health and economic burdens associated with these conditions. In the search for such alternatives, significant efforts have been devised to augment the current and primarily supportive management of renal injury with novel regenerative strategies. For example, gene- and cell-based approaches that utilize recombinant peptides/proteins, gene, cell, organoid, and RNAi technologies have shown promising outcomes primarily in experimental models. Supporting research has also been conducted to improve our understanding of the critical aspects that facilitate the development of efficient gene- and cell-based techniques that the complex structure of the kidney has traditionally limited. This manuscript is intended to communicate efforts that have driven the development of such therapies by identifying the vectors and delivery routes needed to drive exogenous transgene incorporation that may support the treatment of acute and chronic kidney diseases.

show abstract

Section: Of 22mentioning

confidence: 80%

Still Finding Ways to Augment the Existing Management of Acute and Chronic Kidney Diseases with Targeted Gene and Cell Therapies: Opportunities and Hurdles

Corridon¹

2023

Preprint

View full text Add to dashboard Cite

show abstract

“…In line with the same context, a study on ischemic brain injury showed that reduced MEG3 expression was responsible for accelerated angiogenesis [26], a key step in the progression of DN [14,27]. Similarly, Qiu et al, (2016) stated signi cant down-regulation of MEG3 expression in STZ-induced diabetic mice retina and endothelial cells upon high glucose exposure and oxidative stress [28].…”

Section: Discussionmentioning

confidence: 93%

Regulatory Role of Long Non-Coding RNA “Maternally-Expressed Gene-3” in Diabetic Nephropathy through Targeting microRNA-21 and Transforming Growth Factor-Beta

Elwi

El-Din

Rashed

et al. 2022

Preprint

View full text Add to dashboard Cite

Introduction: Diabetic nephropathy (DN) is a leading cause of chronic kidney disease and end-stage renal disease worldwide. The maternally expressed gene-3 (MEG3), a lncRNA, is implicated in the development of diabetic microvascular complications like retinopathy and nephropathy. MicroRNA-21 (miRNA-21) and Transforming Growth Factor-Beta (TGF-β) are established playmakers in fibrogenesis in DN. Research stated that MEG3 can sponge miRNA-21 inhibiting it. Additionally, MEG3 modulates the activity of TGF-β genes by binding to promotor-distal regulatory elements. Aim: Investigate MEG3 regulatory role in DN pathogenesis, and its possible inhibitory effect on miRNA-21 and TGF-β signaling pathway. Methods: The study was performed on 75 subjects divided into 3 groups: 25 controls, 25 diabetics, and 25 DN patients. Participants were subjected to routine laboratory investigations, estimation of gene expression of MEG3 and miRNA-21 by RT-qPCR and measurement of serum TGF-β levels by ELISA. Results: DN group shows a highly significant decrease in MEG-3 relative gene expression, and a significant increase in both miRNA-21 relative gene expression and TGF-β sera levels, when compared to diabetic and control groups. In addition, MEG3 is significantly negatively correlated to miRNA-21, TGF-β1, and HbA1c confirming the sponging effect of MEG3 on miRNA-21 and predicting its potential protective role in DN. On the other hand, there is a statistically significant positive correlation between miRNA-21 gene expression and TGF-β1 levels indicating the up-regulatory role of miRNA-21 on TGF-β1 protein expression levels. Conclusion: Our data suggests that MEG3 is implicated in DN pathogenesis through a possible loop encompassing miRNA-21 and TGF- β1.

show abstract

“…Angiopoietins (Angs) are a family of vascular growth factors that regulate vascular remodeling, maturation, and stability. The Angs family includes Ang 1, Ang 2, Ang 3, and Ang 4, and they interact with tyrosine kinase receptors (Tie 1 and Tie 2) ( Tao et al, 2021 ). Ang 1 and Ang 2 have opposite effects on endothelial cell function.…”

Section: Discussionmentioning

confidence: 99%

Antioxidant and Anti-inflammatory Properties of Resveratrol in Diabetic Nephropathy: A Systematic Review and Meta-analysis of Animal Studies

Lei

Zhang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Accumulated experimental evidence suggests that resveratrol may have an effect on diabetic nephropathy by inhibiting inflammation and decreasing oxidative stress. However, the credibility of the evidence for this practice is unclear. Thus, we aimed to perform a systematic review and meta-analysis of animal studies to evaluate the antioxidant and anti-inflammatory properties of resveratrol when used in the treatment of diabetic nephropathy.Methods: Electronic bibliographic databases including PubMed, EMBASE, and Web of Science were searched for relevant studies. The methodological quality of animal studies was assessed based on the SYstematic Review Center for Laboratory animal Experimentation Risk of Bias (SYRCLE’s RoB) tool. A meta-analysis was performed based on the Cochrane Handbook for Systematic Reviews of Interventions by using RevMan 5.4 software. This study was registered within International Prospective Register of Systematic Reviews (PROSPERO) as number CRD42021293784.Results: Thirty-six qualified studies involving 726 animals were included. There was a significant association of resveratrol with the levels of blood glucose (BG), serum creatinine (Scr), blood urea nitrogen (BUN), catalase (CAT), superoxide dismutase (SOD), malondialdehyde (MDA), glutathione (GSH), glutathione peroxidase (GPx), and interleukin-1β (IL-1β). Nevertheless, resveratrol treatment did not effectively decrease the levels of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). In addition, more remarkable antioxidant and hypoglycemic effects were observed in type 2 diabetic nephropathy rather than in type 1 diabetic nephropathy based on subgroup analysis.Conclusion: In this meta-analysis, resveratrol can exert its antioxidant activities by reducing the levels of MDA and recovering the activities of SOD, CAT, GSH, and GPx. With regard to pro-inflammatory cytokines, resveratrol had a positive effect on the reduction of IL-1β. However, the analysis indicated that resveratrol had no effect on IL-6 and TNF-α levels, probably because of the methodological quality of the studies and their heterogeneity. Current evidence supports the antioxidant and anti-inflammatory properties of resveratrol, but its relationship with the levels of some inflammatory cytokines such as IL-6 and TNF-α in animals with diabetic nephropathy needs further elucidation.

show abstract

Antiangiogenic therapy in diabetic nephropathy: A double‑edged sword (Review)

Cited by 12 publications

References 152 publications

Still Finding Ways to Augment the Existing Management of Acute and Chronic Kidney Diseases with Targeted Gene and Cell Therapies: Opportunities and Hurdles

Still Finding Ways to Augment the Existing Management of Acute and Chronic Kidney Diseases with Targeted Gene and Cell Therapies: Opportunities and Hurdles

Regulatory Role of Long Non-Coding RNA “Maternally-Expressed Gene-3” in Diabetic Nephropathy through Targeting microRNA-21 and Transforming Growth Factor-Beta

Antioxidant and Anti-inflammatory Properties of Resveratrol in Diabetic Nephropathy: A Systematic Review and Meta-analysis of Animal Studies

Contact Info

Product

Resources

About